Celestica (CLS) director Luis Müller to step down; Amar Maletira to lead Audit Committee

Rhea-AI Filing Summary

Celestica Inc. announced that Dr. Luis Müller plans to resign from its Board of Directors, including his roles as Chair of the Audit Committee and member of other board committees, effective at the conclusion of the regularly scheduled meeting on January 28, 2026. The company states that his decision is for personal reasons related to other professional commitments and not due to any disagreement with Celestica regarding its operations, policies, or practices.

To ensure continuity in oversight, the Board has appointed current director Amar Maletira to become Chair of the Audit Committee effective upon Dr. Müller’s resignation. Maletira brings over 25 years of public company business, strategic, and finance leadership experience, including multiple Chief Financial Officer roles, and has been determined by the Board to possess the financial expertise appropriate for this key governance position.

false000103089400010308942025-12-022025-12-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________

FORM 8-K

________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 2, 2025

________________________________________________

Celestica Inc.

(Exact name of registrant as specified in its charter)
________________________________________________

Ontario, Canada			001-14832			98-0185558
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

5140 Yonge Street, Suite 1900						M2N 6L7
Toronto, Ontario, Canada						(Zip Code)
(Address of principal executive officers)

(416) 448-2211

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)  

________________________________________________

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Name of each exchange on which registered

Common Shares without par value

CLS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 2, 2025, Celestica Inc. (the “Company”) was informed by Dr. Luis Müller of his intention to resign from the Board of Directors (the “Board”), as well as from his roles as Chair of the Audit Committee and member of other Board committees, effective at the conclusion of the regularly scheduled meeting on January 28, 2026. Dr. Müller’s decision to resign is for personal reasons in order to focus on other professional commitments and is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Müller will continue to serve in his current capacities and remain fully engaged through the effective date of his resignation.

In connection with Dr. Müller’s planned transition, the Board has appointed the current member of the Board Mr. Amar Maletira as Chair of the Audit Committee, effective upon Dr. Müller’s resignation on January 28, 2026. Mr. Maletira has over 25 years of broad public company business, strategic and finance leadership in numerous enterprise technology industries, including holding various roles as a Chief Financial Officer, and the Board has determined that Mr. Maletira possesses the financial expertise appropriate for service as Chair of the Audit Committee.

Item 9.01.    Financial Statements and Exhibits.

Exhibit No.			Description
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CELESTICA INC.
Date: December 5, 2025
			By:			/s/ Douglas Parker
						Name: Douglas Parker
						Title: Chief Legal Officer and Corporate Secretary

FAQ

What board change did Celestica Inc. (CLS) announce in this 8-K?

Celestica Inc. disclosed that Dr. Luis Müller intends to resign from its Board of Directors, including his roles as Chair of the Audit Committee and member of other board committees, effective at the conclusion of the regularly scheduled meeting on January 28, 2026.

Why is Dr. Luis Müller resigning from the Celestica (CLS) board?

The company states that Dr. Müller is resigning for personal reasons in order to focus on other professional commitments, and that his decision is not due to any disagreement with Celestica regarding its operations, policies, or practices.

Who will chair Celestica Inc.’s Audit Committee after Dr. Müller resigns?

The Board has appointed current director Amar Maletira as the new Chair of the Audit Committee, effective upon Dr. Müller’s resignation on January 28, 2026.

What qualifications does Amar Maletira bring to the Audit Committee chair role at Celestica (CLS)?

Celestica notes that Amar Maletira has over 25 years of broad public company business, strategic, and finance leadership experience in various enterprise technology industries, including serving in multiple Chief Financial Officer roles, and the Board has determined he has the appropriate financial expertise to serve as Audit Committee Chair.

When will Dr. Luis Müller’s resignation from the Celestica board become effective?

Dr. Müller’s resignation is scheduled to become effective at the conclusion of Celestica’s regularly scheduled Board meeting on January 28, 2026. Until then, he will continue to serve in his current roles and remain fully engaged.

Does Celestica Inc. report any disagreements related to this board resignation?

No. Celestica specifies that Dr. Müller’s decision to resign is not due to any disagreement with the company on any matter relating to its operations, policies, or practices.